Infliximab enhances the therapeutic effects of 5-fluorouracil resulting in tumor regression in colon cancer
Citations Over TimeTop 23% of 2016 papers
Abstract
Abstract: Colon cancer (CC) is among the most common malignant diseases with a dismal survival. Tumor necrosis factor-alpha (TNF-α) has been identified as a therapeutic target in various cancers, and anti-TNF-α treatment has shown promising effects in different cancer models. However, if TNF-α can be targeted in CC, the therapeutic values of anti-TNF-α treatment in CC remain unknown. Our study indicated that TNF-α is highly expressed in CC cell lines and patient tumor samples. High expression of TNF-α is an independent adverse prognosticator of CC. Targeting the TNF-α by its antibody infliximab induced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity and enhanced apoptosis leading to cell death. The combination of infliximab with 5-fluorouracil showed better responses in vitro and in vivo than 5-fluorouracil alone. In conclusion, this study identified TNF-α as a target of CC and anti-TNF-α treatment synergized with chemotherapy leading to a better outcome in preclinical models. Keywords: colon cancer, tumor necrosis factor-alpha, chemotherapy, prognosis, tumor regression
Related Papers
- → Alpha-Fetoprotein as a TNF Resistance Factor for the Human Hepatocarcinoma Cell Line HepG2(1997)35 cited
- Mechanisms of tumor necrosis factor cytotoxicity and the cytotoxic signals transduced by the p75-tumor necrosis factor receptor.(1994)
- → Complement-dependent cytotoxicity of anti-human osteogenic sarcoma monoclonal antibodies(1982)8 cited
- → CELLULAR AND HUMORAL IN VITRO CYTOTOXICITY AGAINST AUTOLOGOUS BLADDER TUMOR CELLS IN HUMANS(1981)5 cited
- → Reactivities of Mouse Monoclonal Antibody K2.7 to Renal Cancers in Complement Dependent Cytotoxicity and Antibody Dependent Cell-Mediated Cytotoxicity(1995)